Velcade news from FierceBiotech
NewsGlobal demographic trends threaten drug industry
You can file the following under the category of really, really bleak forecasts: The rising cost of healthcare in the developing world matched by an aging population is creating a perfect storm for Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
Millennium chief scientist takes offbeat approach
The Scientist profiles Millennium Pharmaceuticals CSO Joe Bolen, whose team has been advancing a new therapy that targets molecules "upstream" from Velcade. The data will be released at Read more...
ALSO NOTED: Genentech options Exelixis inhibitor; Millennium reports positive data for cancer cocktail; Immtech CEO takes a pay
> Exelixis announced that Genentech has exercised an option to develop Exelixis' XL518, a selective inhibitor of MEK which is currently in a Phase I clinical trial. Exelixis earns $3 million on Read more...
Europe moves to reclaim center stage
In Europe, venture money is typically harder to come by than in the U.S., but the continent Read more...
ALSO NOTED: Solvay drug 'approvable'; ChemGenex touts trial results: Asuragen raises $18.5M in venture cash; and much more...
> FDA staffers say that Solvay's experimental therapy for atrial fibrillation is approvable--with conditions. Report > Shares of Read more...
ALSO NOTED: GSK cuts 5,000 jobs; Codexis opens Singapore lab; Reliant sets IPO terms;and much more...
> The closure of a GlaxoSmithKline's Puerto Rican plant has kicked off the plan to cut 5,000 jobs. Read more...
ALSO NOTED: Cosmo inks deal; GenMab expands cancer program; OPKO acquires rights Phase III drug; and much more...
> Italy's Cosmo Pharmaceuticals will pick up a €2 million upfront fee after inking a global licensing deal with Ferring for a reformulated budesonide product. Cosmo also could receive up to Read more...
SPOTLIGHT: Positive Velcade data fuels stock rise
Shares of Millennium Pharmaceuticals shot up this morning after the company announced that a late-stage trial of Velcade proved Read more...
| Press ReleasesPRESS RELEASE: Phase III Trial of VELCADE for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates Phase III Trial of VELCADE for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma - Read more... PRESS RELEASE: Phase III Trial in Multiple Myeloma Stopped Early Due to Significant Efficacy Advantage of VELCADE Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE for Injection Based Therapy Across All Endpoints - Millennium on Read more... |
Get more Velcade coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets